Saladax Biomedical Closes $8 Million Series C Financing

Saladax Biomedical, Inc., a Bethlehem, PA-based company which develops novel diagnostic tests for the practical delivery of personalized medicine, closed its $8.4m Series C financing led by Excel Venture Management of Boston.
Participants included Golden Seeds LLC, Ben Franklin Technology Partners, and the Life Sciences Greenhouse of Central Pennsylvania, as well as a number of angel investors.
The company’s products span all stages of development and address a variety of therapeutic areas, with an initial focus in oncology.
The funding will be used to accelerate product development and expand clinical support of Saladax’s MYCARE™ line of diagnostic tests, which measure blood levels of cancer and Central Nervous System (CNS) disorder drugs, providing physicians with guidance to personalize patient dosing for optimal efficacy.
FinSMEs
05/03/2010

Join the discussion